Navigation Links
Elsevier's Biochimica et Biophysica Acta (BBA) journal series adds open access journal: BBA Clinical

Oxford, November 13, 2013, - Elsevier, a world-leading provider of scientific, technical and medical information products and services, announces the launch of BBA Clinical, the first full open access journal within the Biochimica et Biophysica Acta (BBA) journal series. BBA Clinical will focus on translating molecular insights into clinical research.

BBA Clinical is a biomedical journal dedicated to publishing research on the molecular basis of human diseases, as well as presenting findings from clinical trials that target biochemical pathways and processes. All articles in BBA Clinical describe, in part or entirely, studies using human patient samples or human cohorts. Clinical areas of particular interest include aging, cancer, cardiovascular-, metabolic-, neurological-, and immunological diseases; the interactions that may occur among these different diseases and conditions; and studies that examine their early or pre-symptomatic states. Cross-sectional and prospective studies from well-established cohorts, and studies involving imaging methodologies, are particularly encouraged for submission.

"The journal provides a new forum for insights concerning the biochemical mechanisms related to diagnosis, progression, and treatment of a wide range of human diseases," said BBA Clinical Executive Editor, Jeffrey N. Keller from Pennington Biomedical Research Center, Baton Rouge, Louisiana. "BBA Clinical will offer not just a useful forum for clinical research today, but it is designed to be a prominent contributor to the larger overall body of clinical advancements far into the future."

"We are very excited about the launch of BBA Clinical," added Dolors Alsina, Executive Publisher at Elsevier. "The journal will build on our long standing track record as one of the leading international journals focusing on molecular aspects in biology and medicine and will break new ground as the clinical complement to BBA Molecular Basis of Disease."


Contact: Kristian Wilson

Related biology news :

1. Media invited: Biophysical Society Annual Meeting
2. Biophysical Society announces 2013 New and Notable Symposium speakers
3. Biophysical Society announces winners of 2013 international travel awards
4. Biophysical Society announces winners of 2013 Education Committee travel awards
5. Biophysical Society announces winners of 2013 CPOW travel awards
6. Biophysical Society names 2013 Distinguished Service, Emily M. Gray, and Founders awardees
7. Biophysical Society names 5 2013 award recipients
8. Elsevier launches new open access journal: Photoacoustics
9. Winners named in 2013 AAAS Kavli Science Journalism Awards competition
10. Frontiers launches 2 new open-access journals: Frontiers in Earth Science and Frontiers in Environmental Science
11. Frontiers launches a new open-access journal in Cell and Developmental Biology
Post Your Comments:
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - ... ... ... With ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
Breaking Biology Technology: